MedTrace Logo

Implementation of a Pharmacist-led Pharmacogenomic Clinical Service

NCT04984538 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2023-02-01

No results posted yet for this study

Summary

Tabula Rasa HealthCare (TRHC), doing business as CareKinesis, is the first national pharmacy that provides science-based medication risk identification and mitigation technologies and services. CareKinesis utilizes medication decision support tools and pharmacists certified in geriatrics to provide pharmacy services for various healthcare organizations including PACE organizations (described above). Presently, CareKinesis services more than 35 PACE organizations, including approximately 100 PACE sites, across the United States. As a national PACE pharmacy provider since 2011, CareKinesis focuses on improving medication regimens to reduce medication-related risks while enhancing economic, clinical and humanistic outcomes. Pharmacist-led PGx clinical services and medication safety reviews are currently being offered to PACE organizations under the direction of licensed healthcare prescribers by TRHC (CareKinesis). Our aim is to extend and meticulously study PGx testing for more PACE patients and conduct a prospective preemptive PGx study to determine feasibility of implementation and effect on outcomes. After mutual agreement, these services may also be extended to other organizations where TRHC provides pharmacy services, and data will be collected with patient consent.

Conditions

  • Adverse Drug Event
  • Drug Drug Interaction
  • Pharmacogenomics
  • Elderly

Interventions

OTHER

Pharmacogenomic Testing

Cheek swab as a part of routine care

Sponsors & Collaborators

  • Tabula Rasa HealthCare

    lead INDUSTRY

Principal Investigators

  • Veronique Michaud, PhD · Tabula Rasa HealthCare

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-01
Primary Completion
2023-01-30
Completion
2023-01-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04984538 on ClinicalTrials.gov